Blueprint Medicines Corp. logo

Blueprint Medicines Corp. (BPMC)

Market Closed
18 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
129. 46
+0.18
+0.14%
$
8.36B Market Cap
- P/E Ratio
0% Div Yield
2,980,995 Volume
-8.6 Eps
$ 129.28
Previous Close
Day Range
129.46 129.46
Year Range
73.04 129.55
Want to track BPMC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 5 days

Summary

BPMC closed Friday higher at $129.46, an increase of 0.14% from Thursday's close, completing a monthly increase of 0% or $0. Over the past 12 months, BPMC stock gained 47.01%.
BPMC is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 1.66%. On average, the company has surpassed earnings expectations by 0.55%, based on the last three reports. The next scheduled earnings report is due on Jul 30, 2025.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

BPMC Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

The deal announced Monday is Sanofi's third of the year so far.

Barrons | 1 month ago
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.

Zacks | 2 months ago
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript

Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communications Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating Officer Conference Call Participants Marc Frahm - TD Cowen Laura Prendergast - Raymond James Michael Yee - Jefferies Colleen Kusy - Baird Derek Archila - Wells Fargo Brian Cheng - JPMorgan Reni Benjamin - Citizens Ami Fadia - Needham David Dai - UBS Judah Frommer - Morgan Stanley Sudan Loganathan - Stephens Operator Good morning. My name is Angela and I'll be your conference operator today.

Seekingalpha | 2 months ago

Blueprint Medicines Corp. Dividends

BPMC is not paying dividends to its shareholders.

Blueprint Medicines Corp. Earnings

23 Oct 2025 (In 3 months) Date
-
Cons. EPS
-
EPS
7 Aug 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
30 Jul 2025 (In 5 days) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
13 Feb 2025 Date
-
Cons. EPS
-
EPS
BPMC is not paying dividends to its shareholders.
23 Oct 2025 (In 3 months) Date
-
Cons. EPS
-
EPS
7 Aug 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
30 Jul 2025 (In 5 days) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
13 Feb 2025 Date
-
Cons. EPS
-
EPS

Blueprint Medicines Corp. (BPMC) FAQ

What is the stock price today?

The current price is $129.46.

On which exchange is it traded?

Blueprint Medicines Corp. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is BPMC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 8.36B.

When is the next earnings date?

The next earnings report will release on Jul 30, 2025.

Has Blueprint Medicines Corp. ever had a stock split?

No, there has never been a stock split.

Blueprint Medicines Corp. Profile

Biotechnology Industry
Healthcare Sector
Kathryn Haviland CEO
NASDAQ (NGS) Exchange
09627Y109 Cusip
US Country
682 Employees
- Last Dividend
- Last Split
30 Apr 2015 IPO Date

Overview

Blueprint Medicines Corporation is a precision therapy company focused on developing innovative treatments for genomically defined cancers and blood disorders. With operations both in the United States and internationally, the company pioneers in creating targeted therapies aimed at addressing specific genetic markers within cancerous cells and blood disorders. Initially founded as Hoyle Pharmaceuticals, Inc., it underwent a name change to Blueprint Medicines Corporation in June 2011 and has been advancing in the field of precision medicine since its inception in 2008. Headquartered in Cambridge, Massachusetts, Blueprint Medicines is at the forefront of developing a new wave of targeted therapies aimed at improving the lives of patients with serious genetic diseases.

Products and Services

Blueprint Medicines Corporation's pipeline includes several promising investigational drugs in various stages of development, targeting a range of conditions with significant unmet medical needs:

  • AYVAKIT: In development for systemic mastocytosis (SM) and gastrointestinal stromal tumors, AYVAKIT represents the company's dedication to addressing rare and hard-to-treat cancers by targeting specific genetic mutations.
  • BLU-263: An orally available KIT inhibitor, BLU-263 is being developed for the treatment of indolent systemic mastocytosis and other mast cell disorders, showcasing the company's focus on precision medicine in the realm of rare blood disorders.
  • GAVRETO: Targeting RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma, GAVRETO exemplifies Blueprint Medicines’ commitment to lung and thyroid cancer patients with specific genetic alterations.
  • BLU-945: Addressing epidermal growth factor receptor (EGFR) driven non-small-cell lung carcinoma (NSCLC), BLU-945 is tailored for patients with specific EGFR mutations, highlighting the company's efforts in lung cancer precision therapy.
  • BLU-451: Specifically in development for NSCLC patients with EGFR exon 20 insertion mutations, BLU-451 adds to the company's portfolio of targeted lung cancer therapies.
  • BLU-782: Aimed at fibrodysplasia ossificans progressiva, BLU-782 is an example of the company's innovative approach to rare diseases, focusing on conditions with critical needs for effective treatments.
  • BLU-222: This investigational drug is targeted towards patients with cyclin E aberrant cancers, further expanding Blueprint Medicines' oncology pipeline with a focus on precision oncology.
  • BLU-852: Developed for the treatment of advanced cancers, BLU-852 represents the company's broader efforts in tackling various types of advanced-stage malignancies with novel therapeutic approaches.

Additionally, Blueprint Medicines Corporation has forged several strategic collaboration and license agreements to enhance its developmental capabilities and reach. Partnerships with entities like Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd., underline the company's commitment to bringing new, groundbreaking therapies to market through cooperative efforts and shared expertise.

Contact Information

Address: 45 Sidney Street
Phone: 617 374 7580